Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events

This study is being done to find out if patient blood samples can be used to perform individualized modeling of cancer therapy-related side effects.

PRIMARY OBJECTIVES:

I. Generate induced pluripotent stem cells (iPSC's) from patients receiving cancer treatment.

II. Differentiate patient iPSC's into cardiomyocytes and/or neurons or other cell types that may be relevant to modeling cancer therapy-related adverse effects, such as cardiotoxicity and neurotoxicity.

III. Use patient specific iPSC-derived cells to:

IIIa. Model cancer therapy-related toxicities; IIIb. Better understand the mechanisms of toxicities; IIIc. Determine if patient specific genetic variants are causative of toxicities; IIId. Screen novel protective therapies for cancer therapy-related toxicities.

OUTLINE: This is an observational study.

Patients undergo blood sample collection and have their medical records reviewed on study.

Inclusion Criteria:

• Any patient >= 18 years of age
• Previously treated, planned or currently receiving any potentially toxic cancer therapy including but not limited to chemotherapy, targeted and immunotherapies

Exclusion Criteria:

• Inability on the part of the patient to understand the informed consent or be compliant with the protocol